Intuitive Surgical, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David J. Rosa
- Full Time Employees
- 17,021
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 1020 Kifer Road Sunnyvale CA United States of America 94086-5304
- IPO Date
- Jun 16, 2000
- CIK
- 0001035267
- Website
- intuitive.com
- Similar Companies
- Business
- Intuitive Surgical, Inc. develops, manufactures, and markets advanced robotic-assisted surgical systems designed to enhance the quality and access to minimally invasive care globally. Its core products include the da Vinci Surgical System, which enables surgeons to perform a wide range of complex surgical procedures across specialties such as general surgery, urology, gynecology, cardiothoracic, and head and neck surgery using minimally invasive techniques. The company also offers the Ion Endoluminal System, a robotic platform for diagnostic endoluminal procedures enabling minimally invasive lung biopsies through advanced imaging and navigation technology. Intuitive’s product suite includes stapling, energy, and core instrumentation compatible with its multi-port da Vinci systems, alongside progressive learning pathways that facilitate clinical adoption, and a comprehensive infrastructure of service and support including installation, maintenance, technical support, proactive system health monitoring, and integrated digital capabilities that provide hospitals with data-driven insights to optimize surgical performance. Founded in 1995 and headquartered in Sunnyvale, California, Intuitive Surgical operates globally, supporting hospitals and surgical teams across over 60 countries. In the last 1-2 years, the company has advanced the commercial launch of its da Vinci 5 Surgical System, receiving regulatory clearances from the US FDA and CE mark in 2024, with 2025 focused on scaling the adoption of this platform through enhanced hardware and software upgrades featuring increased computing power and digital capabilities. Intuitive reported significant growth in system placements and procedure volumes, with a 14% year-over-year increase in installed base and 17% procedural growth as of mid-2025. Strategic priorities include expanding its robotic surgery ecosystem, reinforcing its recurring revenue model—which accounted for 84% of revenue in 2024—and furthering its Quintuple Aim framework aimed at improving patient outcomes, care team experience, access to care, and lowering total costs. Additionally, leadership transitioned in mid-2025 with President Dave Rosa promoted to CEO, signaling a new phase of growth and innovation focus. Despite rising competition in the robotic surgery field, Intuitive remains a dominant market leader through continuous technological innovation and strategic expansion. This comprehensive offering positions Intuitive Surgical as a pioneer and global leader in robotic-assisted, minimally invasive surgical technology, serving healthcare providers with products, services, and digital innovations that collectively enhance surgical precision, patient recovery, and overall healthcare system efficiency.
Company News
Countdown to Intuitive Surgical (ISRG) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
ISRG Gains Nearly 12% in a Month: Should You Buy, Hold or Sell?
ISRG Is Expanding Beyond Surgery: Here's Why the GI Opportunity Matters
Intuitive Surgical (ISRG) Upgraded to Buy: Here's Why
3 Sales Growth Stocks to Buy as Q3 Earnings Get Underway
Investors Heavily Search Intuitive Surgical, Inc. (ISRG): Here is What You Need to Know
2,558 Intuitive Surgical, Inc. $ISRG Shares Purchased by NorthCrest Asset Manangement LLC
Intuitive Surgical, Inc. $ISRG Stock Acquired by Woodstock Corp
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?
5 Companies Fighting for Control of the Next Robotics Boom
Intuitive Surgical, Inc. (ISRG) Exceeds Market Returns: Some Facts to Consider
Is Intuitive Surgical (ISRG) a Buy as Wall Street Analysts Look Optimistic?
The Monopolistic Razor-and-Blade Engine I Can’t Stop Buying
Intuitive Surgical, Inc. (ISRG) Gains As Market Dips: What You Should Know
Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, AppFolio, Delek US Holdings, Flutter Entertainment, Honeywell Aerospace, Intuitive Surgical, Marvell, NetApp, and More
Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific
Intuitive Surgical: The Multiple Fell, The Story Didn't
3 Medical Instruments Stocks Using GenAI to Navigate Industry Woes
2 Beaten-Down Stocks Worth Buying and Holding for the Next Decade